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Volume 55, Number 3 Letters to the Editor 891exclude “silent” strokes, a predictor of future cognitive deteriora-
tion.
In conclusion, based on the analysis of nearly 1500 CEAs, our
study demonstrates that preoperative treatment with clopidogrel,
particularly when it is continued to the day before surgery, seems to
be associated with a higher risk of neck bleeding after CEA,
requiring re-exploration in most cases.1 Larger studies are war-
ranted to confirm our findings and prevent this feared surgical
complication.
Claudio Baracchini, MD
Department of Neurological Sciences
University of Padua School of Medicine
Padova, Italy
Enzo Ballotta, MD
Vascular Surgery Section
Geriatric Surgery Clinic
Department of Surgical and Gastroenterological Sciences
University of Padua School of Medicine
Padova, Italy
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Regarding “Impact of cilostazol after endovascular
treatment for infrainguinal disease in patients with
critical limb ischemia”
We were delighted to read the recent publication of the work
by Soga et al1 regarding the use of cilostazol in patients with critical
limb ischemia (CLI). To our knowledge, this is the first and
extremely valuable multicenter, retrospective analysis study that
investigates the effects of cilostazol in this cohort of patients.
In our own practice at Barts and The London NHS Trust in
the United Kingdom, we have not used cilostazol to treat patients
with CLI. In England, cilostazol is currently only licensed for use
in patients with claudication but not CLI.2 In Scotland, however,
its use is not licensed at all!
Recently, the National Institute for Health and Clinical Ex-
cellence (NICE), an independent organization responsible for
providing national guidance on promoting good health and pre-
venting and treating ill health in England, decided not to recom-
mend the use of cilostazol for treatment of peripheral vascular
disease for any indication.3 This decision is based on a cost- and
clinical-benefit analysis of National Health Service (NHS) re-
sources. With this higher authority not recommending the use of
cilostazol in patients with claudication and no CLI, in addition to
the current worldwide financial situation, do the authors think the
use of cilostazol in patients with CLI is cost-effective? We noticed
that there is no cost analysis in their study. Did they find a financial
advantage for the use of cilostazol?
This information regarding costing is vital for rationalization
for us to implement the use of cilostazol in this cohort of patients
into our current practice in the United Kingdom. Thiva Dindyal, BSc, MBBS, MRCS (Edin), MRCS (Eng)
onstantinos Kyriakides, MD, FRCS
arts and The London NHS Trust
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We conducted a multicenter retrospective study to evaluate
he economic effectiveness of cilostazol (the purchase price of 200
g cilostazol in the United States is $4.0-$5.2 US dollars) in
atients with critical limb ischemia (CLI), with the understanding
hat this study had many limitations. The efficacy of cilostazol was
etrospectively evaluated in 618 patients who had developed CLI
or the first time.1 No significant difference in overall survival was
ound, but major amputation was significantly decreased in the
ilostazol-treated group. To evaluate the economic effectiveness of
ilostazol, it was assumed that administration of cilostazol did not
hange the mortality and provided a 50% risk reduction in the rate
f major amputation of 20% in 5 years. If 500 of 1000 patients with
LI treated with endovascular therapy are treated with aspirin and
ilostazol and the other 500 with aspirin alone, major amputation
ill be required in 100 patients in the aspirin group and 50 in the
spirincilostazol group over 5 years; therefore, the number
eeded to treat value is 10 (50 of 500). The drug price of cilostazol
t 200 mg per person is 379 yen/day ($4.7 US dollars/day; $1 
80), 138,335 yen/year ($1729 US dollars/year), and 691,675
en/5 years ($8646 US dollars/5 years). Assuming no deaths, it
akes 350 million yen ($4.3 million US dollars) to treat 500
atients with cilostazol for 5 years. Therefore, it is estimated that it
akes approximately 7 million yen ($90,000 US dollars) to prevent
ajor amputation in a patient with CLI. However, the mortality is
ctually around 11% per year, which gives an estimate of 4 to 5
illion yen (%50,000-$62,500 US dollars) to prevent major am-
utation in a patient with CLI. The mean total hospitalization cost
as 3.41 million yen ($43,000 US dollars) and the additional
ospitalization cost due to major amputation was 730,000 yen
$9100 US dollars) in 40 patients who were randomly extracted
rom this study. In patients who did not undergo major amputa-
ion, a hospitalization cost of 390,000 yen ($4900 US dollars) was
dded due to minor amputation and wound treatment. The hos-
italization cost in patients with major amputation was 340,000
en ($4250 US dollars) higher ( cost) than that in patients
ithout major amputation. Although the costs were not the same
n all patients, these results suggest that cilostazol decreased the
ospitalization cost when administered to patients with CLI. The
ealth care costs at other hospitals and the expense of hospital visits
ere not included and these costs should also be considered.The costs estimated in this study are only an approximation.
he economic validity of administration of cilostazol to patients
R1
2
3
4
d
R
p
r
s
s
c
c
t
t
o
u
p
d
m
a
t
n
b
b
t
f
r
p
A
e
p
s
s
i
c
i
c
s
t
M
N
JOURNAL OF VASCULAR SURGERY
March 2012892 Letters to the Editorwith CLI requires evaluation by specialists. This evaluation should
also consider the major decrease in quality of life after major
amputation, the decreased productivity associated with major am-
putation, newly required nursing care costs, and economic and
time burdens on the patient’s family. However, we believe that
cilostazol has been sufficiently evaluated and should be used in
patients in whom the drug is expected to be particularly effective
for major event reduction (age 75 years old, ambulatory, not
receiving dialysis, Rutherford class V), as suggested in Fig 6 of our
original article.1
Yoshimitsu Soga, MD
Department of Cardiology
Kokura Memorial Hospital
Kitakyushu, Japan
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Regarding “Basilic vein transposition versus
biosynthetic prosthesis as vascular access for
hemodialysis”
Morosetti et al present a study concluding that, when possible,
brachiobasilic arteriovenous fistula (BBAVF) should be created in
preference to the insertion of an arteriovenous graft (AVG).1 This
conclusion concurs with those of other studies.2
The AVG group in the current study combines forearm loop
AVGs (FLAVG) and brachioaxillary AVGs (BAAVG). This group-
ing should be considered to be inappropriate, as FLAVG and
BAAVG are not directly comparable. The majority of AVG failures
are due to stenosis at the venous anastomosis. These stenoses do
not lead to draining vein occlusion, or adversely affect the arterial
inflow.3 The placement of a FLAVG should not therefore prevent
the future creation of a BBAVF. The formation of a BBAVF,
however, does preclude the formation of a FLAVG as, following
occlusion of the basilic vein, only BAAVG can be considered. It is
perhaps more appropriate to consider the FLAVG as a halfway
house between a primary access (radiocephalic or brachiocephalic
AVF), and a secondary access (BBAVF or BAAVG), and as such
FLAVGs should be considered separately to BAAVGs.
A large multicenter randomized study directly comparing
BBAVF and FLAVG showed that although primary patency rates
are lower and complication rates higher in grafts, secondary pa-
tency rates were equivalent between the two groups.4
Although primary and secondary patency data in isolation are
important for assessing the efficacy of a vascular access interven-
tion, just as important is the effect that the intervention has on
subsequent access attempts and longevity. Thus, as described
above, as FLAVG does not preclude BBAVF formation and does
not reduce venous capital, it may therefore increase the longevity
of total vascular access attempts in that arm. Conversely, creation
of BBAVF precludes FLAVG, reduces venous capital, and thus
reduces the overall longevity of vascular access in that limb.
Finally, it is noteworthy that FLAVG with modern self-sealing
grafts can allow almost immediate vascular access for emergency
dialysis and act as a medium-term bridge to more definitive dialysis
access.
Philip James Yates, MD, MRCS (Ed)
Department of Transplant Surgery
Queen Elizabeth Hospital
Birmingham, United Kingdom
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The comparison between the present study1 and those re-
orted in the other references2,3 is not correct. In fact, they are
etrospective studies, while our study is a randomized one (so the
tatistical power of our results is stronger despite the minor sample
ize).
Our data are not so far different from those reported in the
urrent literature on this topic. In fact, most of the authors
onclude that native vascular accesses show a better primary pa-
ency when compared with the prosthetic ones. Moreover, most of
he authors consider prosthetic vascular accesses (VA) as a whole as
ne single group for follow-up, regardless of the different config-
rations and insertion sites. This is the reason why we gathered
rosthetic VA in one batch as well.
Basilic vein stenosis and consequent thrombosis, which could
evelop after a forearm loop arterovenous graft implantation, in
ost cases makes basilic vein itself fully unusable for transposition,
nd in any case, it reduces the vessel length (which is itself a limit to
ransposition because often the vascular segment available for
eedle puncturing is not so long).
The randomized study by Keuter et al4 compares “autogenous
rachial-basilic fistula in the upper arm (BBAVF) or a prosthetic
rachial-antecubital forearm loop (PTFE loop),” which are exactly
he same VA kinds we considered. This puts in evidence the fact that
orearm arterovenous grafts (AVGs) and basilic vein transposition
epresent two concurring chances for the surgeon in compromised
atients. This study concludes that primary patency (PP) is lower for
VGs. In our study, we found that PP was higher for BBAVF; that is
xactly the same conclusion. Similarly, results regarding secondary
atency are superimposable between the two studies.
As regards the impact of a specific kind of VA set-up on
ubsequent attempts and longevity, keeping in mind the need to
pare patient’s vessels, we could state that a loop AVG could be
mplanted anyway after BBAVF thrombosis, using a brachial artery
omitans vein.
Finally, we fully agree on the possibility of using AVGs as an
mmediate vascular access in selected patients. In fact, in our
onclusions, we state that “given the shorter time to use, in
ubjects showing compromised clinical conditions and in who a
emporary VA is not reliable, AVG could be the first choice.”
assimo Morosetti, MD
ephrology and Dialysis Department
G.B. Grassi” Hospital
ome, Italy
